In Brief: Scimed/Organogenesis
This article was originally published in The Gray Sheet
Executive Summary
Scimed/Organogenesis: Sign letter of intent to develop and commercialize collagen-coated endovascular stents for treatment of ischemic heart disease and peripheral vascular disease. The stents will "combine Organogenesis' collagen technologies with Scimed stent and catheter technologies," Organogenesis says. The non-thrombogenic nature of the collagen coating would give the stents "significant benefits not available" in currently marketed devices, according to the company. Under terms of the deal, Scimed would pay Organogenesis $11 mil. in upfront and milestone payments, as well as royalties and manufacturing payments. Scimed also would fund both companies' research and development efforts in this area...